 ENCINITAS, Calif., May 05, 2022 GLOBE NEWSWIRE -- Ventyx Biosciences, Inc. Nasdaq: VTYX, Ventyx, a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. 